Literature DB >> 31267817

The relationship between CRP gene polymorphism (rs2794521, rs3091244), ASDAS-CRP and ASDAS-ESR in ankylosing spondylitis.

Meliha Kasapoğlu Aksoy1, Lale Altan1,2, Orhan Görükmez3, Altuğ Güner1, Koray Ayar4.   

Abstract

Background: We aimed to investigate the haplotypes and alleles of two variants (rs2794521 and rs3091244) in AS patients and to examine their relationship with ASDAS-CRP and ASDAS-ESR values.
Methods: We evaluated 160 AS patients diagnosed according to the ASAS criteria. ASDAS-CRP and ASDAS-ESR values were calculated. ESR and CRP were examined. The restriction fragment length polymorphism (RFLP) method was used for detecting the rs2794521 and rs3091244 regions on the CRP gene.
Results: As a result of the evaluation of rs2794521 gene polymorphism using PCR, TT, TC and CC genotypes were observed in 90, 81 and 9 individuals, respectively. As a result of the evaluation of rs3091244 gene polymorphism, CC, AC and TT genotypes were observed in 104, 51 and 5 individuals, respectively. T allele and C allele were found in rs2794521 gene by 75% and 25%, respectively. In addition, T allele, C allele and A allele were found in rs3091244 gene by 80%, 17% and 3%, respectively. With the help of regression equation, ASDAS-CRP level was 0.34 units higher in cases with rs3091244 C allele than cases without rs3091244 C alleles.
Conclusion: CRP rs3091244 C allele may be associated with the increased relative risk for ASDAS-CRP.

Entities:  

Keywords:  ASDAS CRP; ASDAS ESR; Ankylosing spondylitis; CRP gene polymorphism; acute phase reactants

Year:  2019        PMID: 31267817     DOI: 10.1080/14397595.2019.1639916

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  1 in total

1.  Association between C-reactive protein gene variant and treatment efficacy of etanercept in ankylosing spondylitis patients receiving hip arthroplasty.

Authors:  Yuansheng Xu; Wei Jiang; Hui Zhang
Journal:  J Clin Lab Anal       Date:  2020-04-20       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.